Don't expect February's nonfarm payrolls report to repeat January's upside surprise
Seeking Alpha News (Thu, 5-Mar 2:37 PM ET)
TipRanks (Thu, 5-Mar 5:10 AM ET)
TipRanks (Thu, 5-Mar 5:01 AM ET)
Rising employee health insurance costs dampened wage growth: Fed survey
Seeking Alpha News (Wed, 4-Mar 11:58 AM ET)
Business Wire (Tue, 3-Mar 10:00 AM ET)
Barclays Reaffirms Their Buy Rating on Elevance Health (ELV)
TipRanks (Tue, 3-Mar 4:46 AM ET)
Globe Newswire (Mon, 2-Mar 7:41 PM ET)
Elevance Health drops as CMS threatens to block enrollment in Medicare drug plans
Seeking Alpha News (Mon, 2-Mar 2:43 PM ET)
Notable healthcare headlines for the week: Viatris, Novo Nordisk, and Gilead Sciences in focus
Seeking Alpha News (Sun, 1-Mar 9:05 AM ET)
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of June 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
Elevance Health trades on the NYSE stock market under the symbol ELV.
As of March 5, 2026, ELV stock price declined to $286.48 with 2,908,738 million shares trading.
ELV has a beta of 0.24, meaning it tends to be less sensitive to market movements. ELV has a correlation of 0.01 to the broad based SPY ETF.
ELV has a market cap of $63.23 billion. This is considered a Large Cap stock.
Last quarter Elevance Health reported $49 billion in Revenue and $3.33 earnings per share. This fell short of revenue expectation by $-161 million and exceeded earnings estimates by $.23.
In the last 3 years, ELV traded as high as $567.26 and as low as $273.71.
The top ETF exchange traded funds that ELV belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
ELV has underperformed the market in the last year with a price return of -26.2% while the SPY ETF gained +19.4%. ELV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.1% and -17.3%, respectively, while the SPY returned -0.2% and -0.7%, respectively.
ELV support price is $284.59 and resistance is $298.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELV shares will trade within this expected range on the day.